Skip to main content
Download PDF

Effects of different doses of glucocorticoids on postoperative atrial fibrillation: a meta-analysis

BMC Cardiovascular Disorders volume 23, Article number: 16 (2023) Cite this article

Abstract

Background

Postoperative atrial fibrillation (POAF) is the most common arrhythmia after cardiac surgery, and its occurrence is closely related to inflammation. This paper intends to apply meta-analysis to investigate the effect of glucocorticoids on POAF.

Methods

PubMed, Embase, Web of Science, and Cochrane Library were searched using the internationally recognized systematic evaluation and retrieval strategy. Two review authors independently selected relevant studies and extracted data based on the Cochrane handbook for systematic reviews of interventions approach. Stata 17 was used for data analysis. In the subgroup analysis, we grouped the participant data according to differences in glucocorticoids dose and type of surgery. At the same time, we also conducted a meta-analysis on the possible infection and gastrointestinal injury caused by glucocorticoids use.

Results

27 studies and 14,442 patients were finally included. Results from the random-effects model indicated that the incidence of POAF was lower in glucocorticoid group (RR 0.80, 95% CI 0.71–0.92, P = 0.001). According to the subgroup analysis result, low doses of glucocorticoids reduced the incidence of POAF (RR 0.81, 95% CI 0.71–0.92, P = 0.001). The effect of high doses glucocorticoids on the POAF was not statistically significant (RR 0.81, 95% CI 0.56–1.19, P = 0.286). In the coronary artery bypass grafting (CABG) subgroup, the glucocorticoids reduced the incidence of POAF (RR 0.71, 95% CI 0.58–0.87, P = 0.001). In the CABG OR Valvular Surgery group, the effect of glucocorticoids on POAF was not statistically significant (RR 0.88, 95% CI 0.75–1.03, P = 0.108). 15 studies documented postoperative complications of infection, two studies were excluded from the system because the end point event was 0, and meta-analysis showed no increased risk of infection from glucocorticoid use (RR 0.85, 95% CI 0.68–1.06, P = 0.158). Eight studies documented the effects of glucocorticoids on gastrointestinal diseases, and meta-analysis showed no differences between the two groups (RR 1.12, 95% CI 0.83–1.50, P = 0.450).

Conclusion

The use of glucocorticoids can reduce the incidence of POAF. The subgroup analysis result showed that low-dose glucocorticoids were more effective than high-dose glucocorticoids in inhibiting POAF. The use of glucocorticoids in CABG alone can better inhibit the occurrence of POAF. The effects of glucocorticoids on infection and gastrointestinal injury were not statistically significant.

Review registration: PROSPERO, CRD42022304521.

Peer Review reports

Introduction

POAF is the most common arrhythmia after CABG and valve surgery, with an overall incidence of 20% to 40% and a higher incidence of approximately 30% to 50% in valve surgery [1]. POAF is closely relevant to stroke, hospital stay time, and the cost of treatment [2, 3]. The pathological mechanism of POAF is very complex, and it is related to many factors. At present, the study about POAF is increasing rapidly, but no clear conclusion has been reached. Relevant research found that the main influencing factors are structure and electrical reconstruction. Furthermore, an increased adrenergic tone and changes in metabolic milieus are also possible mechanisms of POAF [4].

Data suggests that inflammation might lead to the POAF [5]. Trauma, ischemia/reperfusion, and cardiopulmonary bypass during cardiac surgery can induce systemic inflammation; this inflammatory response is closely related to the occurrence of POAF [6,7,8,9]. Glucocorticoids can inhibit inflammation and, as a result, may decrease the POAF risk. The effects of glucocorticoids on POAF have been researched widely in many countries. According to previous study result, glucocorticoids reduce postoperative C-reactive protein (CRP) levels, leukocytes, and other inflammatory markers; but the conclusions of these studies are controversial [10, 11]. Thus, we conducted this meta-analysis to investigate the effect of glucocorticoids on POAF.

Methods

Literature search strategy and criteria

PubMed, Embase, and Cochrane Library were searched based on internationally recognized systematic evaluation and retrieval strategy. Retrieval of data began from the establishment of the database through December 2021. The search terms were as follows: “Postoperative atrial fibrillation”, “POAF”, “Cardiac surgery”, “CABG”, “Cardiac valve surgery”, “atrial fibrillation”, “AF”, “Glucocorticoids”, “Glucocorticoid”, “Steroid”, “Corticosteroid” and other individual drug names. Articles were also identified by referring to the references of each study to supplement the data.

Inclusion and exclusion criteria

Inclusion criteria: (1) randomized controlled trial (RCT) with glucocorticoids treatment and placebo control; (2) all patients required surgical treatment and had no atrial fibrillation before surgery, where the types of procedures included were CABG, cardiac valve surgery, and CABG combined with valve surgery; (3) published literature.

Exclusion criteria: (1) age less than 18 years; (2) cardiovascular risk factors were not considered as primary or secondary endpoints; (3) the full text of the study is not available.

Quality assessment and data extraction

This meta-analysis was reported per the Preferred reporting items for systematic reviews and Meta-Analyses (PRISMA) guidelines.

The data collected in this study were screened and extracted by 2 researchers (Zhongzheng Zhou and Xin He) in strict accordance with the exclusion criteria according to the established retrieval strategy. The Cochrane risk-of-bias assessment tool (RoB 2) was used to evaluate literature bias [12]. Figure 1 shows the flowchart of the literature retrieval (Additional file 1).

Fig. 1
figure 1

Flowchart of literature retrieval

Full size image

Statistical treatment

In this study, the correlation of glucocorticoids and POAF risk was evaluated by indexes of relative risk (RR) and 95% confidence interval (CI). The RR was used to evaluated glucocorticoids group and placebo group, the glucocorticoids group refers to the use of glucocorticoids before or after surgery, while placebo group refers to the use of an equal dose of saline as placebo. Both Cochran’s Q test and I2 index were applied to measure the heterogeneity, where heterogeneity was quantified by I2, the range of which is 0 to 100% (judge criteria I2 = 0–25%, no; I2 = 25–50%, low; I2 = 50–75%, moderate; I2 = 75–100%, high heterogeneity). In the comprehensive effect study, the random effect model was selected, and subgroup analysis was conducted according to different doses. On this basis, the possible sources of heterogeneity were discussed. The possibility of publication bias was evaluated by Egger test method [13]. The sensitivity is determined by excluding one study at a time, and then the impact of a single study on the overall research results is analyzed. The judgment basis of statistical difference was set as P < 0.05. Stata 17 software was used for data analysis.

In addition, two subgroup analyses were conducted, the first subgroup research was conducted based on the dose of glucocorticoids. Patients who were administered dexamethasone doses lower or equal to 100 mg were placed in the low-dose group, and patients who were administered dexamethasone doses higher than 100 mg were classified into high-dose group (where different types of glucocorticoids are converted to equivalent doses of dexamethasone). Previous studies indicated that 100 mg dexamethasone might achieve a balance between efficacy and safety, so we used the 100 mg dose as the standard for subgroup analysis [39]. Second, we divided them into CABG group and CABG OR Valvular surgery group for subgroup analysis according to different surgical types, where the CABG group refers to patients who underwent CABG alone, and the CABG OR Valvular surgery group refers to patients who had valve surgery or CABG combined with valve surgery.

Results

Literature search

The literature search process is depicted in Fig. 1. 3743 studies were identified by searching each database according to the search keywords. The titles, abstracts, and full texts of the initially detected literature were read, and 27 studies were included based on above criteria [14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40].

Study characteristics

Across the included studies, 14,442 patients were enrolled. Table 1 shows the basic feature and quality assessment results of the selected studies. The regions involved in these studies mainly include the EU, Asia and USA Interventions in the trial group included dexamethasone, methylprednisolone, and hydrocortisone. Figure 2 summarizes the results of quality assessment of each study according to the Cochrane risk-of-bias assessment tool (RoB 2).

Table 1 Basic information of the studies
Full size table
Fig. 2
figure 2

Quality assessment of each included study. A Risk bias plot, B Summary of risk of bias

Full size image

Correlation between glucocorticoids and POAF

A total of 27 studies evaluated the influence of glucocorticoids on POAF; in total, there were 7260 cases in glucocorticoids group and 7182 cases in control group. According to the result of Fig. 3, incidence of POAF in glucocorticoid group is lower (RR 0.80, 95% CI 0.71–0.92, P = 0.001). In certain range, low doses glucocorticoids can reduce the POAF risk (RR 0.81, 95% CI 0.71–0.92, P = 0.001). The risk of POAF was not significantly different between the high-dose glucocorticoids group and the placebo group (RR 0.81, 95% CI 0.56–1.19, P = 0.286). In the CABG subgroup, the glucocorticoids reduced the POAF risk (RR 0.71, 95% CI 0.58–0.87, P = 0.001). In the CABG OR Valvular Surgery group, the effect of glucocorticoids on POAF was not statistically significant (RR 0.88, 95% CI 0.75–1.03, P = 0.108) (see Table 2).

Fig. 3
figure 3

A Meta-analysis of the correlation of the first subgroup. B Meta-analysis of the correlation of the second subgroup

Full size image
Table 2 Subgroup analysis of the of the primary outcome
Full size table

A total of 15 studies documented postoperative complications of infection. However, two studies were excluded from the system because the end point event was 0, and meta-analysis showed no increased risk of infection from glucocorticoid use (RR 0.85, 95% CI 0.68–1.06, P = 0.158) (see Fig. 4). And 8 studies documented the effects of glucocorticoids on gastrointestinal diseases, and meta-analysis showed no differences between the glucocorticoid and the control group (RR 1.12, 95% CI 0.83–1.50, P = 0.450) (see Fig. 5).

Fig. 4
figure 4

Meta-analysis of the correlation of glucocorticoids and postoperative infection

Full size image
Fig. 5
figure 5

Meta-analysis of correlation of glucocorticoids and gastrointestinal injury

Full size image

Publication bias evaluation and sensitivity analysis

In the research process, publication bias were evaluated based on Egger’s test, and the relevant result is shown in Fig. 6. The results of Egger's test were close to the critical value, suggesting that there might be publication bias in the analysis results (P = 0.050). Sensitivity analysis was conducted on the three study endpoints. We used the leave-one-out analysis method for sensitivity analysis. The vertical axis represents the study type, and the horizontal axis represents the combined results after excluding a certain study. Sensitivity analysis results showed that excluding any study, the combined results of the remaining studies would not affect the end point outcome, proving that the conclusion was stable (see Fig. 7).

Fig. 6
figure 6

Egger’s publication bias plot of glucocorticoids and POAF

Full size image
Fig. 7
figure 7

A Sensitivity analysis of glucocorticoid to POAF; B Sensitivity analysis of glucocorticoid to infection; C Sensitivity analysis of glucocorticoid to gastrointestinal injury

Full size image

Discussion

Meta-analysis was used to judge the effect of glucocorticoids use on POAF. The results showed a lower POAF risk in glucocorticoids group, while subgroup analysis showed that low-dose glucocorticoids decreased the incidence of POAF compared to high-dose glucocorticoids. Previous studies on the influence of glucocorticoids on POAF were controversial; some previous studies have yielded positive results, while others have been negative. Past studies included small sample sizes, Van Osch's study was a single-center substudy of the DECS study [38], and the SIRS study [39] was a large controlled trial. Their results suggest that glucocorticoids have no correlation with the incidence of POAF. But the controlled experiment conducted by Al-Shawabkeh in 2016 suggested that glucocorticoids reduced the incidence of that [40]. Therefore, we included patients with all types of surgery for this meta-analysis.

POAF usually occurs during the initial 4 days after cardiac surgery; it is closely related to the type of surgery, with an incidence about (20–30%) in CABG surgery, (30–50%) in valvular surgery and a higher incidence in valvular combined coronary artery bypass surgery (60–80%) [41, 42]. Some school found that the occurrence of POAF is closely related to the prolongation of postoperative hospital stay and the increases in treatment cost [43, 44]. POAF is usually self-limited, and most of cases return to normal on their own within 24 h of onset [45]; although some patients will relapse within 2 days of the first attack [46]. The pathogenesis of POAF is mainly related to local inflammatory reaction [47, 48], adrenergic activation [49], electrolyte disturbances [50], atrial stimulation [51] and prolonged mechanical ventilation [42]. Among them, the inflammatory response is considered to be the most important pathogenesis of POAF [52]. The concentrations of CRP [53], number of white blood cells in POAF patients are higher than those in patients with sinus rhythm [54, 55]; the increase of these inflammatory indicators is closely related to the occurrence of POAF [56, 57]. Glucocorticoids can effectively reduce inflammatory reactions [58], thus reducing the incidence of POAF.

The anti-inflammatory mechanism of glucocorticoids is mainly through inhibiting the activity of immunomodulatory transcription factors such as NF-KB,AP-1, which is dose-dependent. The higher the dose, the stronger the inhibition effect [59]. But in our study, it was found that compared to the high-dose glucocorticoids, low-dose glucocorticoids were more effective in inhibiting the occurrence of POAF. There are a few possible causes for this observation. First, high doses of glucocorticoids cause high expression of calcium regulator mRNA, which can shorten the action potential refractory period and induce arrhythmia. Oakley analyzed the signal pathways related to dysregulated genes, and the results showed that the mechanism of glucocorticoids on POAF might be as follows: improving the expression of voltage-gated L-type calcium channel (LTCC), sarcoplasmic/endoplasmic reticulum calcium adenosine triphosphatase 2 (SERCA2), sodium/calcium exchanger 1 (NCX1) and RyR2 genes, this result has important reference value for the pathological study of POAF [60, 61]; this abnormal expression may contribute to the development of arrhythmias. Second, glucocorticoids can activate the renin–angiotensin–aldosterone system (RASS) system, leading to increased blood pressure, rapid heart rate [62, 63]. High doses of glucocorticoids over-activate the RASS system and the sympathetic nervous system, increasing the risk of arrhythmias. Third, intravenous methylprednisolone alters myocardial cell stimulation thresholds and sodium metabolism. These changes may lead to the variation of electrolyte shifts in the membranes of the heart muscle, result in arrhythmias [64, 65]. Fourth, the use of high doses of glucocorticoids can induce insulin resistance, which may prevent glucose from entering cardiac muscle cells, aggravate an ischemic injury, and induce arrhythmias [49].Low-doses of glucocorticoids are less likely to cause these adverse reactions and may have a better control effect on POAF. We investigated the influence of glucocorticoids on AF after different types of surgery, glucocorticoids reduced the incidence of POAF in CABG group, but the effect of glucocorticoids in combined group was not statistically significant. We hypothesized that this may be due to the lower incidence of POAF and the lower inflammatory response in CABG alone.

The main side effects of glucocorticoids are gastrointestinal bleeding and an high risk of infection, which limits the application of glucocorticoids in heart surgery. We also conducted a meta-analysis of these risks, 12,126 cases were enrolled in 15 studies to assess the effects of glucocorticoids on infections including mediastinal, pulmonary, digestive and urinary tract infections, suggesting that glucocorticoids use did not lead to an higher risk of infection. Besides, a total of 11,155 patients were enrolled in 8 studies to assess the effect of glucocorticoids on gastrointestinal injury, including postoperative gastrointestinal bleeding, vomiting, gastrointestinal ulceration, or gastrointestinal dysfunction, meta-analysis results suggested that the effect of glucocorticoids on gastrointestinal injury was not significant. The present results seem to be at variance with our past consensus, and we speculate that this may be due to the shorter duration of glucocorticoid use in all studies and the smaller single dose, which needs to be confirmed in more and larger controlled trials. In addition to increased risk of infection and gastrointestinal damage, the use of glucocorticoids may cause abnormal glucose tolerance, electrolyte disorder, abnormal fat metabolism, osteoporosis, slow wound healing, nervous system abnormalities, and even lead to thromboembolism. When the drug is stopped for a long time, it can also lead to withdrawal reaction, adrenal cortical dysfunction, hypotension, and even shock. These side effects also limit the further use of glucocorticoids.

Limitations

Firstly, the heterogeneity of the primary end points was too high. Subgroup analysis was conducted, but our grouping criteria were established in advance. In the second subgroup analysis, we found a significant reduction in heterogeneity in the CABG group, in the CABG OR Valvular Surgery group, the heterogeneity was significantly higher than that in the CABG group due to the inclusion of patients undergoing combined surgery. And in valve surgery, different valve lesions have different effects on cardiac function. Therefore, we believe that the differences in surgical methods are the main reason for the heterogeneity. In future trials, we plan to conduct more rigorous surgical classification to reduce heterogeneity. Due to the differences in drug sensitivity among the included population and the large differences in the dose of glucocorticoids used in each subgroup, this may be another factor leading to the generation of heterogeneity. We analyzed and discussed the source of heterogeneity in Limitations and finally choose to use random effect model to synthesize heterogeneity, and we cautiously recommend the final conclusion. Secondly, there was a lack of recent large clinical studies.

Conclusions

The results of this study showed that glucocorticoids were beneficial in reducing the effect of POAF, and low-dose glucocorticoids could reduce the incidence of POAF. However, heterogeneity of overall study and subgroup analysis was high, so we held a cautious recommendation. Our study also did not find that glucocorticoids use increased the risk of infection and gastrointestinal injury.

Availability of data and materials

We declare that the data supporting the conclusions of this article are fully described within the article.

Abbreviations

POAF:

Postoperative atrial fibrillation

CRP:

C-reactive protein

CABG:

Coronary artery bypass graft

RCT:

Randomized controlled trial

PRISMA:

The Preferred reporting items for systematic reviews and Meta-Analyses

CI:

Confidence interval

RR:

Relative risk

LTCC:

L-type calcium Channel

SERCA2:

Sarcoplasmic/endoplasmic reticulum calcium adenosine triphosphatase 2

NCX1:

Sodium/calcium exchanger 1

RASS:

Renin–angiotensin–aldosterone system

RoB 2:

Cochrane risk-of-bias assessment tool (RoB 2)

References

  1. Bessissow A, Khan J, Devereaux PJ, Alvarez-Garcia J, Alonso-Coello P. Postoperative atrial fibrillation in non-cardiac and cardiac surgery: an overview. J Thromb Haemost. 2015;13(Suppl 1):S304–12. https://doi.org/10.1111/jth.12974.

    Article  Google Scholar 

  2. Almassi GH, Schowalter T, Nicolosi AC, Aggarwal A, Moritz TE, Henderson WG, et al. Atrial fibrillation after cardiac surgery: a major morbid event? Ann Surg. 1997;226(4):501–11; discussion 511–3. https://doi.org/10.1097/00000658-199710000-00011.

  3. Hakala T, Pitkänen O, Hippeläinen M. Feasibility of predicting the risk of atrial fibrillation after coronary artery bypass surgery with logistic regression model. Scand J Surg. 2002;91(4):339–44. https://doi.org/10.1177/145749690209100406.

    Article  CAS  Google Scholar 

  4. Anselmi A, Possati G, Gaudino M. Postoperative inflammatory reaction and atrial fibrillation: simple correlation or causation? Ann Thorac Surg. 2009;88(1):326–33. https://doi.org/10.1016/j.athoracsur.2009.01.031.

    Article  Google Scholar 

  5. Shingu Y, Kubota S, Wakasa S, Ooka T, Tachibana T, Matsui Y. Postoperative atrial fibrillation: mechanism, prevention, and future perspective. Surg Today. 2012;42(9):819–24. https://doi.org/10.1007/s00595-012-0199-4.

    Article  Google Scholar 

  6. Fillinger MP, Rassias AJ, Guyre PM, Sanders JH, Beach M, Pahl J, et al. Glucocorticoid effects on the inflammatory and clinical responses to cardiac surgery. J Cardiothorac Vasc Anesth. 2002;16(2):163–9. https://doi.org/10.1053/jcan.2002.31057.

    Article  Google Scholar 

  7. Marik PE, Fromm R. The efficacy and dosage effect of corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a systematic review. J Crit Care. 2009;24(3):458–63. https://doi.org/10.1016/j.jcrc.2008.10.016.

    Article  CAS  Google Scholar 

  8. Jakubová M, Mitro P, Stančák B, Sabol F, Kolesár A, Cisarik P, et al. The occurrence of postoperative atrial fibrillation according to different surgical settings in cardiac surgery patients. Interact Cardiovasc Thorac Surg. 2012;15(6):1007–12. https://doi.org/10.1093/icvts/ivs361.

    Article  Google Scholar 

  9. Dieleman JM, de Wit GA, Nierich AP, Rosseel PM, van der Maaten JM, Hofland J, et al. Long-term outcomes and cost effectiveness of high-dose dexamethasone for cardiac surgery: a randomised trial. Anaesthesia. 2017;72(6):704–13. https://doi.org/10.1111/anae.13853.

    Article  CAS  Google Scholar 

  10. Jansen NJ, van Oeveren W, van den Broek L, Oudemans-van Straaten HM, Stoutenbeek CP, Joen MC, et al. Inhibition by dexamethasone of the reperfusion phenomena in cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1991;102(4):515–25.

    Article  CAS  Google Scholar 

  11. El Azab SR, Rosseel PM, de Lange JJ, Groeneveld AB, van Strik R, van Wijk EM, et al. Dexamethasone decreases the pro- to anti-inflammatory cytokine ratio during cardiac surgery. Br J Anaesth. 2002;88(4):496–501. https://doi.org/10.1093/bja/88.4.496.

    Article  Google Scholar 

  12. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https://doi.org/10.1136/bmj.l4898.

    Article  Google Scholar 

  13. Lin L, Chu H. Quantifying publication bias in meta-analysis. Biometrics. 2018;74(3):785–94. https://doi.org/10.1111/biom.12817.

    Article  Google Scholar 

  14. Chaney MA, Nikolov MP, Blakeman B, et al. Pulmonary effects of methylprednisolone in patients undergoing coronary artery bypass grafting and early tracheal extubation. Anesth Analg. 1998;87(1):27–33.

    Article  CAS  Google Scholar 

  15. Schurr UP, Zünd G, Hoerstrup SP, et al. Preoperative administration of steroids: influence on adhesion molecules and cytokines after cardiopulmonary bypass. Ann Thorac Surg. 2001;72(4):1316–20.

    Article  CAS  Google Scholar 

  16. Yared JP, Starr NJ, Torres FK, Bashour CA, Bourdakos G, Piedmonte M, et al. Effects of single dose, postinduction dexamethasone on recovery after cardiac surgery. Ann Thorac Surg. 2000;69(5):1420–4. https://doi.org/10.1016/s0003-4975(00)01180-2.

    Article  CAS  Google Scholar 

  17. Fillinger MP, Rassias AJ, Guyre PM, et al. Glucocorticoid effects on the inflammatory and clinical responses to cardiac surgery. J Cardiothorac Vasc Anesth. 2002;16(2):163–9.

    Article  Google Scholar 

  18. Halvorsen P, Ræder J, White PF, Almdahl SM, Nordstrand K, Saatvedt K, et al. The effect of dexamethasone on side effects after coronary revascularization procedures. Anesth Analg. 2003;96(6):1578–83. https://doi.org/10.1213/01.ANE.0000063922.90966.3A.

    Article  CAS  Google Scholar 

  19. Oliver WC Jr, Nuttall GA, Orszulak TA, et al. Hemofiltration but not steroids results in earlier tracheal extubation following cardiopulmonary bypass: a prospective, randomized double-blind trial. Anesthesiology. 2004;101(2):327–39.

    Article  Google Scholar 

  20. Prasongsukarn K, Abel JG, Jamieson WR, Cheung A, Russell JA, Walley KR, et al. The effects of steroids on the occurrence of postoperative atrial fibrillation after coronary artery bypass grafting surgery: a prospective randomized trial. J Thorac Cardiovasc Surg. 2005;130(1):93–8. https://doi.org/10.1016/j.jtcvs.2004.09.014.

    Article  CAS  Google Scholar 

  21. Sano T, Morita S, Masuda M, et al. Minor infection encouraged by steroid administration during cardiac surgery. Asian Cardiovasc Thorac Ann. 2006;14(6):505–10.

    Article  Google Scholar 

  22. Enc Y, Karaca P, Ayoglu U, et al. The acute cardioprotective effect of glucocorticoid in myocardial ischemia-reperfusion injury occurring during cardiopulmonary bypass. Heart Vessels. 2006;21(3):152–6.

    Article  Google Scholar 

  23. Whitlock RP, Young E, Noora J, et al. Pulse low dose steroids attenuate post-cardiopulmonary bypass SIRS. SIRS I J Surg Res. 2006;132(2):188–94.

    Article  CAS  Google Scholar 

  24. Halonen J, Halonen P, Järvinen O, Taskinen P, Auvinen T, Tarkka M, et al. Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial. JAMA. 2007;297(14):1562–7. https://doi.org/10.1001/jama.297.14.1562.

    Article  CAS  Google Scholar 

  25. Yared JP, Bakri MH, Erzurum SC, Moravec CS, Laskowski DM, Van Wagoner DR, et al. Effect of dexamethasone on atrial fibrillation after cardiac surgery: prospective, randomized, double-blind, placebo-controlled trial. J Cardiothorac Vasc Anesth. 2007;21(1):68–75. https://doi.org/10.1053/j.jvca.2005.10.014.

    Article  CAS  Google Scholar 

  26. Sobieski MA 2nd, Graham JD, Pappas PS, et al. Reducing the effects of the systemic inflammatory response to cardiopulmonary bypass: can single dose steroids blunt systemic inflammatory response syndrome? ASAIO J. 2008;54(2):203–6.

    Article  CAS  Google Scholar 

  27. Amr YM, Elmistekawy E, El-Serogy H. Effects of dexamethasone on pulmonary and renal functions in patients undergoing CABG with cardiopulmonary bypass. Semin Cardiothorac Vasc Anesth. 2009;13(4):231–7.

    Article  Google Scholar 

  28. Weis F, Beiras-Fernandez A, Schelling G, et al. Stress doses of hydrocortisone in high-risk patients undergoing cardiac surgery: effects on interleukin-6 to interleukin-10 ratio and early outcome. Crit Care Med. 2009;37(5):1685–90.

    Article  CAS  Google Scholar 

  29. Mauermann WJ, Nuttall GA, Cook DJ, Hanson AC, Schroeder DR, Oliver WC. Hemofiltration during cardiopulmonary bypass does not decrease the incidence of atrial fibrillation after cardiac surgery. Anesth Analg. 2010;110(2):329–34. https://doi.org/10.1213/ANE.0b013e3181c76bd3.

    Article  Google Scholar 

  30. Vukovic PM, Maravic-Stojkovic VR, Peric MS, et al. Steroids and statins: an old and a new anti-inflammatory strategy compared. Perfusion. 2011;26(1):31–7.

    Article  Google Scholar 

  31. Murphy GS, Sherwani SS, Szokol JW, et al. Small-dose dexamethasone improves quality of recovery scores after elective cardiac surgery: a randomized, double-blind, placebo-controlled study. J Cardiothorac Vasc Anesth. 2011;25(6):950–60.

    Article  CAS  Google Scholar 

  32. Mirhosseini SJ, Forouzannia SK, Sayegh AH, Sanatkar M. Effect of prophylactic low dose of methylprednisolone on postoperative new atrial fibrillation and early complications in patients with severe LV dysfunction undergoing elective off-pump coronary artery bypass surgery. Acta Med Iran. 2011;49(5):288–92.

    Google Scholar 

  33. Kilger E, Heyn J, Beiras-Fernandez A, et al. Stress doses of hydrocortisone reduce systemic inflammatory response in patients undergoing cardiac surgery without cardiopulmonary bypass. Minerva Anestesiol. 2011;77(3):268–74.

    CAS  Google Scholar 

  34. Dieleman JM, Nierich AP, Rosseel PM, et al. Intraoperative high-dose dexamethasone for cardiac surgery: a randomized controlled trial. JAMA. 2012;308(17):1761–7.

    Article  Google Scholar 

  35. Abbaszadeh M, Khan ZH, Mehrani F, et al. Perioperative intravenous corticosteroids reduce incidence of atrial fibrillation following cardiac surgery: a randomized study. Rev Bras Cir Cardiovasc. 2012;27(1):18–23.

    Article  Google Scholar 

  36. Suezawa T, Aoki A, Kotani M, Tago M, Kobayashi O, Hirasaki A, et al. Clinical benefits of methylprednisolone in off-pump coronary artery bypass surgery. Gen Thorac Cardiovasc Surg. 2013;61(8):455–9. https://doi.org/10.1007/s11748-013-0206-8.

    Article  Google Scholar 

  37. Jacob KA, Dieleman JM, Nathoe HM, et al. The effects of intraoperative dexamethasone on left atrial function and postoperative atrial fibrillation in cardiac surgical patients. Neth Heart J. 2015;23(3):168–73.

    Article  CAS  Google Scholar 

  38. Van Osch D, Dieleman JM, van Dijk D, Jacob KA, Kluin J, Doevendans PA, et al; DExamethasone for Cardiac Surgery (DECS) study group; DExamethasone for Cardiac Surgery DECS study group. Dexamethasone for the prevention of postoperative atrial fibrillation. Int J Cardiol. 2015;182:431–7. https://doi.org/10.1016/j.ijcard.2014.12.094.

  39. Whitlock RP, Devereaux PJ, Teoh KH, Lamy A, Vincent J, Pogue J, et al. SIRS Investigators. Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(10000):1243–1253. https://doi.org/10.1016/S0140-6736(15)00273-1.

  40. Al-Shawabkeh Z, Al-Nawaesah K, Anzeh RA, et al. Use of short-term steroids in the prophylaxis of atrial fibrillation after cardiac surgery. J Saudi Heart Assoc. 2017;29(1):23–9.

    Article  Google Scholar 

  41. Echahidi N, Pibarot P, O’Hara G, Mathieu P. Mechanisms, prevention, and treatment of atrial fibrillation after cardiac surgery. J Am Coll Cardiol. 2008;51(8):793–801. https://doi.org/10.1016/j.jacc.2007.10.043.

    Article  CAS  Google Scholar 

  42. Helgadottir S, Sigurdsson MI, Ingvarsdottir IL, Arnar DO, Gudbjartsson T. Atrial fibrillation following cardiac surgery: risk analysis and long-term survival. J Cardiothorac Surg. 2012;7:87. https://doi.org/10.1186/1749-8090-7-87.

    Article  Google Scholar 

  43. Aranki SF, Shaw DP, Adams DH, Rizzo RJ, Couper GS, VanderVliet M, et al. Predictors of atrial fibrillation after coronary artery surgery. Current trends and impact on hospital resources. Circulation. 1996;94(3):390–7. https://doi.org/10.1161/01.cir.94.3.390.

    Article  CAS  Google Scholar 

  44. Hravnak M, Hoffman LA, Saul MI, Zullo TG, Whitman GR. Resource utilization related to atrial fibrillation after coronary artery bypass grafting. Am J Crit Care. 2002;11(3):228–38.

    Article  Google Scholar 

  45. Auer J, Weber T, Berent R, Ng CK, Lamm G, Eber B. Risk factors of postoperative atrial fibrillation after cardiac surgery. J Card Surg. 2005;20(5):425–31. https://doi.org/10.1111/j.1540-8191.2005.2004123.x.

    Article  Google Scholar 

  46. Mathew JP, Fontes ML, Tudor IC, Ramsay J, Duke P, Mazer CD, et al. Investigators of the Ischemia Research and Education Foundation; Multicenter Study of Perioperative Ischemia Research Group. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA. 2004;291(14):1720–9. https://doi.org/10.1001/jama.291.14.1720.

  47. Ishii Y, Schuessler RB, Gaynor SL, Yamada K, Fu AS, Boineau JP, et al. Inflammation of atrium after cardiac surgery is associated with inhomogeneity of atrial conduction and atrial fibrillation. Circulation. 2005;111(22):2881–8. https://doi.org/10.1161/CIRCULATIONAHA.104.475194.

    Article  CAS  Google Scholar 

  48. Gaudino M, Andreotti F, Zamparelli R, Di Castelnuovo A, Nasso G, Burzotta F, et al. The -174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation Is atrial fibrillation an inflammatory complication? Circulation. 2003;108(Suppl 1):II195–9. https://doi.org/10.1161/01.cir.0000087441.48566.0d.

    Article  CAS  Google Scholar 

  49. Hogue CW Jr, Domitrovich PP, Stein PK, Despotis GD, Re L, Schuessler RB, Kleiger RE, et al. RR interval dynamics before atrial fibrillation in patients after coronary artery bypass graft surgery. Circulation. 1998;98(5):429–34. https://doi.org/10.1161/01.cir.98.5.429.

    Article  Google Scholar 

  50. Mathew JP, Fontes ML, Tudor IC, Ramsay J, Duke P, Mazer CD, et al. Investigators of the Ischemia Research and Education Foundation; Multicenter Study of Perioperative Ischemia Research Group. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA. 2004;291(14):1720–9. doi: https://doi.org/10.1001/jama.291.14.1720.

  51. Funk M, Richards SB, Desjardins J, Bebon C, Wilcox H. Incidence, timing, symptoms, and risk factors for atrial fibrillation after cardiac surgery. Am J Crit Care. 2003;12(5):424–33; quiz 434–5.

  52. Dimmer C, Tavernier R, Gjorgov N, Van Nooten G, Clement DL, Jordaens L. Variations of autonomic tone preceding onset of atrial fibrillation after coronary artery bypass grafting. Am J Cardiol. 1998;82(1):22–5. https://doi.org/10.1016/s0002-9149(98)00231-8.

    Article  CAS  Google Scholar 

  53. Bruins P, te Velthuis H, Yazdanbakhsh AP, Jansen PG, van Hardevelt FW, de Beaumont EM, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation. 1997;96(10):3542–8. https://doi.org/10.1161/01.cir.96.10.3542.

    Article  CAS  Google Scholar 

  54. Lamm G, Auer J, Weber T, Berent R, Ng C, Eber B. Postoperative white blood cell count predicts atrial fibrillation after cardiac surgery. J Cardiothorac Vasc Anesth. 2006;20(1):51–6. https://doi.org/10.1053/j.jvca.2005.03.026.

    Article  Google Scholar 

  55. Ishida K, Kimura F, Imamaki M, Ishida A, Shimura H, Kohno H, et al. Relation of inflammatory cytokines to atrial fibrillation after off-pump coronary artery bypass grafting. Eur J Cardiothorac Surg. 2006;29(4):501–5. https://doi.org/10.1016/j.ejcts.2005.12.028.

    Article  Google Scholar 

  56. Hak Ł, Myśliwska J, Wieckiewicz J, Szyndler K, Siebert J, Rogowski J. Interleukin-2 as a predictor of early postoperative atrial fibrillation after cardiopulmonary bypass graft (CABG). J Interferon Cytokine Res. 2009;29(6):327–32. https://doi.org/10.1089/jir.2008.0082.2906.

    Article  CAS  Google Scholar 

  57. Bruins P, te Velthuis H, Eerenberg-Belmer AJ, Yazdanbakhsh AP, de Beaumont EM, Eijsman L, et al. Heparin-protamine complexes and C-reactive protein induce activation of the classical complement pathway: studies in patients undergoing cardiac surgery and in vitro. Thromb Haemost. 2000;84(2):237–43.

    CAS  Google Scholar 

  58. Patti G, Chello M, Candura D, Pasceri V, D’Ambrosio A, Covino E, Di Sciascio G. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation. 2006;114(14):1455–61. https://doi.org/10.1161/CIRCULATIONAHA.106.621763.

    Article  CAS  Google Scholar 

  59. Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335(1):2–13. https://doi.org/10.1016/j.mce.2010.04.005.

    Article  CAS  Google Scholar 

  60. Oakley RH, Cruz-Topete D, He B, Foley JF, Myers PH, Xu X, et al. Cardiomyocyte glucocorticoid and mineralocorticoid receptors directly and antagonistically regulate heart disease in mice. Sci Signal. 2019;12(577):eaau9685. https://doi.org/10.1126/scisignal.aau9685.

    Article  Google Scholar 

  61. Cruz-Topete D, Oakley RH, Carroll NG, He B, Myers PH, Xu X, et al. Deletion of the cardiomyocyte glucocorticoid receptor leads to sexually dimorphic changes in cardiac gene expression and progression to heart failure. J Am Heart Assoc. 2019;8(15):e011012. https://doi.org/10.1161/JAHA.118.011012.

    Article  CAS  Google Scholar 

  62. Yang S, Zhang L. Glucocorticoids and vascular reactivity. Curr Vasc Pharmacol. 2004;2(1):1–12. https://doi.org/10.2174/1570161043476483.

    Article  Google Scholar 

  63. Sato A, Suzuki H, Nakazato Y, Shibata H, Inagami T, Saruta T. Increased expression of vascular angiotensin II type 1A receptor gene in glucocorticoid-induced hypertension. J Hypertens. 1994;12(5):511–6.

    Article  CAS  Google Scholar 

  64. Kumari R, Uppal SS. First report of supraventricular tachycardia after intravenous pulse methylprednisolone therapy, with a brief review of the literature. Rheumatol Int. 2005;26(1):70–3. https://doi.org/10.1007/s00296-005-0589-7.

    Article  Google Scholar 

  65. Moretti R, Torre P, Antonello RM, Zorzon M, Cazzato G. Recurrent atrial fibrillation associated with pulse administration of high doses of methylprednysolone: a possible prophylactic treatment. Eur J Neurol. 2000;7(1):130. https://doi.org/10.1046/j.1468-1331.2000.00026.x.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

None.

Funding

This work was supported by The Scientific Research Institution Performance Incentive and Guidance Special Project of Chongqing (cstc2019jxj1130010).

Author information

Authors and Affiliations

  1. Department of Cardiology, Chongqing Traditional Chinese Medicine Hospital, Chongqing, 400025, China

    Zhongzheng Zhou, Yi Long, Xin He & Yong Li

Authors
  1. Zhongzheng Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yi Long
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xin He
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

ZZ and YL designed the methods and carried out the statistical analyses. ZZ, XH and YL made substantial contributions to the acquisition and analysis of the data and to the interpretation of data. All the authors contributed to the data extraction, drafted the article, and approved the final version of the manuscript.

Corresponding author

Correspondence to Yi Long.

Ethics declarations

Ethics approval and consent to participate

This article does not contain any studies with human participants or animals performed by any of the authors.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1.

Literature retrieval Method.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhou, Z., Long, Y., He, X. et al. Effects of different doses of glucocorticoids on postoperative atrial fibrillation: a meta-analysis. BMC Cardiovasc Disord 23, 16 (2023). https://doi.org/10.1186/s12872-022-03001-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12872-022-03001-0

Keywords

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us